Skip to main content
OpenTrials
Completed

NCT Number: NCT00544895

Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants

NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from www.neobrain.eu)

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Medizinische Universität Innsbruck, Innsbruck, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestational age < 28 weeks

Treatment and study plan

Primary outcomes

  1. Brain white matter damage (WMD, defined by MRI ,US, EEG)

    Time frame: during stay in NICU and until discharge

Secondary outcomes

  1. Developmental assessment

    Time frame: at 2 years of age

Sponsors and collaborators

Lead sponsor

Hannover Medical School

Other

Collaborators

  • European Commission

Registry information

Acronym: NEOBRAIN

Important dates

Study start
2007
Study completion
2010
First posted
Oct 16, 2007
Registry last updated
Jun 23, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.